These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10160478)

  • 1. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.
    Coyle D
    Pharmacoeconomics; 1996 Jun; 9(6):506-16. PubMed ID: 10160478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.
    Clemens K; Townsend R; Luscombe F; Mauskopf J; Osterhaus J; Bobula J
    Pharmacoeconomics; 1995 Aug; 8(2):169-74. PubMed ID: 10155611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics: an emerging discipline.
    Letizia C
    Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common errors and controversies in pharmacoeconomic analyses.
    Byford S; Palmer S
    Pharmacoeconomics; 1998 Jun; 13(6):659-66. PubMed ID: 10179701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging standardization in pharmacoeconomics.
    Mullins CD; Ogilvie S
    Clin Ther; 1998; 20(6):1194-202; discussion 1192-3. PubMed ID: 9916612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, analysis and presentation of multinational economic studies: the need for guidance.
    Pang F
    Pharmacoeconomics; 2002; 20(2):75-90. PubMed ID: 11888360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?
    van Dongen JM; El Alili M; Varga AN; Guevara Morel AE; Jornada Ben A; Khorrami M; van Tulder MW; Bosmans JE
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):27-37. PubMed ID: 31731882
    [No Abstract]   [Full Text] [Related]  

  • 8. [Methods for analyzing uncertainty].
    Ferriols R; Alós M
    Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomics--an aid to better decision-making.
    Arenas-Guzman R; Tosti A; Hay R; Haneke E;
    J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():34-9. PubMed ID: 16120204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rationale of pharmacoeconomic analysis in rheumatologic indications.
    Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological hurdles in conducting pharmacoeconomic analyses.
    Rizzo JD; Powe NR
    Pharmacoeconomics; 1999 Apr; 15(4):339-55. PubMed ID: 10537953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation.
    Mullahy J
    Med Care; 1996 Dec; 34(12 Suppl):DS124-35. PubMed ID: 8969321
    [No Abstract]   [Full Text] [Related]  

  • 13. The problem of protocol driven costs in pharmacoeconomic analysis.
    Coyle D; Lee KM
    Pharmacoeconomics; 1998 Oct; 14(4):357-63. PubMed ID: 10344904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What do international pharmacoeconomic guidelines say about economic data transferability?
    Barbieri M; Drummond M; Rutten F; Cook J; Glick HA; Lis J; Reed SD; Sculpher M; Severens JL;
    Value Health; 2010 Dec; 13(8):1028-37. PubMed ID: 20667054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines.
    Knies S; Severens JL; Ament AJ; Evers SM
    Value Health; 2010 Aug; 13(5):519-27. PubMed ID: 20712601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines.
    Ramaekers BL; Joore MA; Grutters JP
    Value Health; 2013; 16(5):855-62. PubMed ID: 23947981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?
    Coyle D; Tolley K
    Pharmacoeconomics; 1992 Aug; 2(2):153-62. PubMed ID: 10146954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of confidence intervals and sample size calculations in health economic studies.
    Sacristán JA; Day SJ; Navarro O; Ramos J; Hernández JM
    Ann Pharmacother; 1995; 29(7-8):719-25. PubMed ID: 8520090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of pharmacoeconomic research in China: A systematic review.
    Ma H; Jian W; Xu T; He Y; Rizzo JA; Fang H
    Medicine (Baltimore); 2016 Oct; 95(41):e5114. PubMed ID: 27741131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.